NanoViricides, Inc. (NYSE American: NNVC) announced that a Phase II clinical trial of its antiviral candidate NV-387 for the treatment of MPox is expected to begin soon in the Democratic Republic of Congo, with site preparation and staff training scheduled for early April 2026. The study, already approved by the DRC regulatory agency, will evaluate the safety and effectiveness of NV-387 against Clade I MPox, as the company advances regulatory development and seeks Orphan Drug Designation from the U.S. FDA.
The news is significant because MPox, particularly the Clade I strain prevalent in Central Africa, has caused outbreaks with higher mortality rates. Currently, there are limited treatment options specifically approved for MPox. NV-387 is a broad-spectrum antiviral drug candidate that NanoViricides is also developing for other viral infections, including respiratory syncytial virus (RSV), COVID-19, and influenza. If successful, this trial could lead to an effective therapy for MPox, addressing an unmet medical need in affected regions.
NV-387 is part of NanoViricides' novel nanoviricide technology platform, which uses specially designed nanomaterials to target and destroy viruses. The company's lead drug candidate, NV-387, is not encapsulated with remdesivir, unlike its other candidate NV-CoV-2-R. The company believes that NV-387's broad-spectrum activity could provide a treatment option for multiple viral diseases.
According to the press release, the trial is expected to begin soon, with site preparation and staff training in early April 2026. The DRC regulatory agency has already approved the study, indicating a streamlined process. NanoViricides is also seeking Orphan Drug Designation from the U.S. FDA, which would provide incentives for development of treatments for rare diseases.
The company has a Memorandum of Understanding with TheraCour Pharma, Inc. for the development of drugs based on nanoviricide technology. NanoViricides holds exclusive licenses for several antiviral applications, including HIV, hepatitis B and C, rabies, herpes, influenza, dengue, and certain coronaviruses. The company intends to obtain licenses for RSV, poxviruses, and enteroviruses if initial research is successful.
Investors should note that drug development is lengthy and capital-intensive, and there is no assurance that NV-387 will prove safe and effective in clinical trials. However, the initiation of a Phase II trial marks a critical step forward. For more information, visit the full press release at https://ibn.fm/4Ckhk.
About NanoViricides: The company is a clinical-stage firm focused on creating nanomaterials for antiviral therapy. Its lead candidate NV-387 is being developed for multiple indications, and the company has a pipeline targeting various viral diseases. More details are available at https://www.nanoviricides.com.
